Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02844907 · ClinicalTrials.gov registry record · Phase 4
Regulation of Insulin Secretion by the GLP-1 Receptor
A Phase 4 study, sponsored by VA Office of Research and Development.
- Terminated
- Registry status
- Phase 4
- Development phase
- 6
- Enrollment target
NCT02844907: Clinical Trial Phase 4 study, sponsored by VA Office of Research and Development.
NCT02844907 is a Phase 4 study that was terminated before completion, run by VA Office of Research and Development. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02844907, a Phase 4 study, was terminated before completion, sponsored by VA Office of Research and Development.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 6 participants
- Enrollment target
Study Summary
AIM2: The purpose of Aim-2 of this study is to determine the role of basal GLP-1 action on the beta-cell response to insulin resistance. Healthy subjects will have fasting GLP-1 action determined with GLP-1r blockade before and after induction of experimental insulin resistance. The investigators hypothesize that fasting GLP-1 action will increase to compensate for experimental insulin resistance. AIM3: The purpose of Aim-3 of this study is to determine the role of basal GLP-1 action on fasting glucose regulation in lean, obese, pre-diabetic and type 2 diabetic (T2DM) subjects. A cross sectional study of age-matched subjects across the spectrum of glucose tolerance will be used to test the hypothesis that fasting GLP-1 action increases as beta-cell function declines.
Interventions
- DRUG Dexamethasone
- DRUG Exendin (9-39)
- OTHER Hyperglycemic Clamp
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-07-01 |
| Est. Completion | 2021-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02844907
The ClinicalTrials.gov registry entry for NCT02844907 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT02844907 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02844907 about?
NCT02844907 is a clinical study titled "Regulation of Insulin Secretion by the GLP-1 Receptor". AIM2: The purpose of Aim-2 of this study is to determine the role of basal GLP-1 action on the beta-cell response to insulin resistance. Healthy subjects will have fasting GLP-1 action determined with GLP-1r blockade before and after induction of experimental insulin resistance. The investigators hy...
What is the current status of trial NCT02844907?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 6 participants. The study started on 2018-07-01. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT02844907?
The interventions under investigation include: Dexamethasone (DRUG), Exendin (9-39) (DRUG), Hyperglycemic Clamp (OTHER).
Who is sponsoring clinical trial NCT02844907?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.